Quectel response to FCC about IoT module security
7.9.2023 16:03:00 EEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today commented on the recent letter and response being published by the FCC and the Select Committee of the US Congress questioning if Quectel’s IoT modules represent a potential security risk.
“We welcome the opportunity to work with the FCC and other U.S. government entities to demonstrate our compliance and best practice device security approach, says Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “We are committed to contributing to the advancement of a smarter world by delivering best-in-class and secure products. This commitment is evidenced by our extensive device OEM customer base and our constant focus on providing our customers with the best and most secure modules in the industry.”
The Select Committee to the US Congress’ letter to the FCC had several misconceptions about how Quectel modules work. Quectel’s clarification regarding the statements made in the letter is as follows.
Committee letter: “Connectivity modules are typically controlled remotely and are the necessary link between the device and the internet.”
Quectel’s U.S. customers or their customers’ third-party suppliers/service providers handle device and data management exclusively. Firmware updates are managed and controlled by the device original equipment manufacturer (OEM), not Quectel.
Committee letter: “Serving as the link between the device and the internet, these modules have the capacity both to brick the device and to access the data flowing from the device to the web server that runs each device”
The control of Quectel modules resides with the microcontroller unit (MCU) or central processing unit (CPU) embedded within the customer's device. Quectel itself does not possess any control; instead, this authority rests solely with the OEM – the entity responsible for developing the device. Remote management of the device is achievable solely through the OEM's device management platform. A notable instance of this, referred to in the letter, is the widely covered case involving John Deere agricultural equipment, where just the OEM typically can disable the equipment by accessing and shutting down its own MCU’s controlling the machine.
Committee letter: “As a result, if the CCP can control the module, it may be able to effectively exfiltrate data or shut down the IoT device.”
Once Quectel modules leave the factory and are delivered to its customers, Quectel customers own the data, and Quectel has no access to any of the data collected. The ownership, control, storage, and modification of the data generated by IoT devices within the market firmly rest with the OEM device makers and its customers. Even in the rare cases outside of the U.S. where Quectel resells the connectivity service of a wireless carrier, Quectel does not have access to the device data.
Committee letter: “This raises particularly grave concerns in the context of critical infrastructure and any type of sensitive data.”
Applications that require high security, such as critical infrastructure, typically use private access point names (APNs) and other methods which strictly control and monitor network access. This can be used to control and monitor any data flowing to and from the device. Critical infrastructure is meticulously fashioned with a multi-tiered security approach defined and implemented solely by the device OEM, not Quectel.
The cellular industry is heavily regulated and requires intensive testing and accreditation. Carrier and regulatory certifications are executed by trusted third-party labs and carrier labs, assuring that the module complies with strict technical requirements. The Quectel modules have obtained certifications from the FCC, PCS Type Certification Review Board (PTCRB) and major carriers throughout the world, which underlines Quectel’s commitment to meeting rigorous industry standards.
In addition to cellular modules, Quectel also provides Wi-Fi, Bluetooth and GNSS modules and antennas. As a GSMA member, Quectel and its carrier partners comply with all cellular industry regulations and applicable standards to ensure that end customer data is securely transmitted between customer device and mobile network operator. Quectel does not have access to ANY of the device data.
Quectel is committed to delivering high-quality, best-in-class, secure modules and go above and beyond industry standard practices by conducting independent third-party cyber security audits. More recently Quectel also retained the security firm Finite State, which is auditing and penetration testing the security of its modules through rigorous security testing, improved software supply chain visibility, and comprehensive software risk management. Quectel is also participating in the formulation of new industry security certification standards, such as the CTIA Cybersecurity Certification Working Group and pursuing additional cyber security certifications from various U.S. entities as new standards are formulated and adopted.
Qualcomm manufactures the chipsets and software platforms that are at the core of the Quectel modules. “Our Qualcomm partnership underlines the importance we place on working with well-trusted and secure partners from across the ecosystem to deliver high-quality solutions globally,” Mr. Muhrer continues. “Quectel's impact on the global IoT industry is profound. We supplied millions of cellular modules to support the distribution of Covid-19 vaccines for leading U.S. and global organizations including Pfizer, Johnson & Johnson, and other leading suppliers of vaccines. This underscores our commitment to playing a pivotal role in critical global initiatives.”
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X (formerly known as Twitter).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230907525548/en/
Contact information
Media contact: media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
